Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ROIV
ROIV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ROIV News
Citi and H.C. Wainwright Raise Roivant Sciences Price Targets Following Positive Drug Data
1d ago
Yahoo Finance
Roivant Sciences (ROIV.US) Officer Plans to Sell $5.3 Million in Common Stock via Form 144
1d ago
moomoo
Top Performing Large-Cap Stocks Last Week
Feb 08 2026
Benzinga
Roivant Sciences Q3 2025 Earnings Call Highlights
Feb 06 2026
seekingalpha
U.S. Markets Increased on Friday; Strategy Reached New Heights
Feb 06 2026
Barron's
Roivant Sciences Stock Soars on Positive Phase 2 Results for Brepocitinib
Feb 06 2026
Benzinga
Molina Healthcare Stock Plummets 29% After Earnings Miss
Feb 06 2026
Benzinga
U.S. Stocks Rise, AutoNation Shares Surge
Feb 06 2026
Benzinga
U.S. Stocks Rise as Dow Jones Gains Over 700 Points
Feb 06 2026
Benzinga
Priovant Reports Positive Mid-Stage Trial Results for Brepocitinib in Cutaneous Sarcoidosis
Feb 06 2026
seekingalpha
Roivant Sciences Reports Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
Feb 06 2026
stocktwits
Pulmovant Completes Enrollment in PHocus Trial for PH-ILD
Feb 06 2026
Globenewswire
Brepocitinib Shows Significant Efficacy in Cutaneous Sarcoidosis
Feb 06 2026
Newsfilter
Brepocitinib Shows Positive Phase 2 Results in Cutaneous Sarcoidosis
Feb 06 2026
Newsfilter
S&P 500 Futures Rise in Pre-Market Session; Doximity and Stellantis Underperform
Feb 06 2026
Barron's
Roivant Sciences Reports Q3 Earnings Miss
Feb 06 2026
seekingalpha
Show More News
